Hek5 Inhibitors
Chemical inhibitors of Hek5 function by targeting various signaling pathways and protein kinases that are upstream or directly associated with the activity of Hek5. Staurosporine, a broad-spectrum kinase inhibitor, blocks the ATP binding site on kinases, thereby inhibiting the phosphorylation activity essential for Hek5 function. Similarly, Bisindolylmaleimide I, as a protein kinase C (PKC) inhibitor, and Wortmannin and LY294002, both phosphoinositide 3-kinases (PI3K) inhibitors, disrupt upstream signaling pathways. The inhibition of PKC and PI3K reduces the phosphorylation signaling cascade, leading to a decrease in Hek5 activation. Inhibitors like U0126 and PD98059 selectively target MEK, a kinase upstream of ERK, which is part of the MAP kinase pathway. By inhibiting MEK, these chemicals indirectly prevent the activation of ERK-dependent kinases such as Hek5.
Further, SP600125, a JNK inhibitor, and SB203580, a p38 MAP kinase inhibitor, disrupt the MAP kinase pathway, which can be integral to Hek5 activation. By inhibiting these kinases, the chemicals decrease the functional activity of Hek5 by preventing necessary phosphorylation events. PP2, an Src family kinase inhibitor, reduces the activation of Src family members that may regulate the activity of Hek5. In addition, Lapatinib, an inhibitor of EGFR and HER2, and Gefitinib, an EGFR inhibitor, block the receptor tyrosine kinases that are often involved in the phosphorylation and activation of downstream kinases like Hek5. Lastly, Sorafenib, which inhibits RAF, among other kinases, disrupts downstream signaling that is necessary for the full functional activity of Hek5. Each of these inhibitors, by targeting specific molecules within signaling pathways, ultimately leads to a reduction in Hek5 kinase activity through a cascade of disrupted phosphorylation events or inhibited kinase interactions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which are vital for various signaling pathways. Hek5, being a kinase, can be inhibited by staurosporine through its action of blocking the ATP binding site, resulting in the prevention of phosphorylation events that Hek5 would normally facilitate. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I selectively inhibits protein kinase C (PKC), which is upstream of many kinase pathways, including those involving Hek5. Inhibition of PKC can lead to reduced activation of Hek5 due to decreased phosphorylation signaling, which is necessary for Hek5's kinase activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and PI3K signaling is often involved in the activation of downstream kinases. By inhibiting PI3K, the phosphorylation and activation of Hek5 can be reduced, as PI3K is part of the signaling cascade that leads to Hek5 activation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which in turn inhibits the ERK pathway. Hek5 can be functionally inhibited by U0126 since ERK pathway activity can be necessary for the full activation of downstream kinases, including potentially Hek5. By blocking MEK, the activation of Hek5 through this pathway can be diminished. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can lead to functional inhibition of Hek5 by preventing the activation of downstream kinase signaling pathways that are necessary for Hek5 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, and by inhibiting JNK, the phosphorylation of substrates that may be involved in the same signaling pathways as Hek5 can be decreased. This can lead to a reduction in the functional activity of Hek5 as it may rely on JNK-mediated signaling for its activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. Inhibition of p38 MAP kinase can lead to reduced activation of downstream kinases, potentially including Hek5, as p38 MAP kinase is part of various signaling cascades that can regulate the activity of other kinases. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Since members of the Src kinase family can regulate other kinases, inhibition of these kinases can lead to decreased phosphorylation and activation of Hek5. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor similar to U0126. It can functionally inhibit Hek5 by preventing the activation of the ERK pathway, which might be necessary for Hek5's activation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is an EGFR and HER2 inhibitor. By inhibiting these receptors, the downstream activation of related kinases, including Hek5, can be impaired. This is because the phosphorylation events typically triggered by EGFR and HER2 activity may be part of the activation process for Hek5. | ||||||